🟢 Summit Therapeutics is trading 5% up today amid broader market rebound

Summit Therapeutics is trading at $15.39, up 5.19%; no direct cause for the move is established.

• On October 19, the company announced a global Phase II ivonescimab study in advanced kidney cancer, planning about 100 patients across U.S. and China sites; the announcement did not link the study to the share move.
• No Q3 results were reported; earnings remained estimated for October 19.
• The Nasdaq Composite rose 0.79% and the S&P 500 gained 0.36%, providing broader-market context only.